A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple Sclerosis.

Salter Amber Robert J Fox Gary R Cutter Kathryn C FitzgeraldKate E NicholJoshua R SteinermanKarry M J Smith

Published in: International journal of MS care (2021)

Despite concerns about insufficient safety and efficacy data, legality, and cost, almost one-third of NARCOMS Registry respondents report having tried nonprescription cannabis products in an attempt to alleviate their symptoms. Given the lack of efficacy and safety data on such products, future research in this area is warranted.

Keyphrases

multiple sclerosis
electronic health record
big data
depressive symptoms
machine learning
white matter
data analysis
sleep quality
physical activity